Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ib/II study of DX126-262 in HER2-overexpressing unresectable locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma
CTR20220870Phase 2Active
- Sponsor
- Hangzhou DAC Biotech
- Start
- Jul 2022
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of DX126-262 in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by Hangzhou DAC Biotech. Started Jul 2022; status: active.
02
Drugs
DX126-262
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on CTR20220870.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20220870.